Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Domainex Researchers Identify Small-Molecule Inhibitors of TBK1/IKKepsilon Affecting IL-17 Signaling

Published: Monday, November 05, 2012
Last Updated: Monday, November 05, 2012
Bookmark and Share
Inhibitors may have utility in autoimmune disease treatment.

Domainex Ltd. has developed a number of chemical series with potent and selective activity against two closely-related kinases TBK1 and IKKepsilon.

IL-17 mediated signaling is known to induce the expression of cytokines and other effectors that can cause a variety of immunological diseases such as psoriasis and Chronic Obstructive Pulmonary Disease (COPD).

Domainex researchers are now the first to report that small-molecule inhibitors of TBK1/IKKepsilon are able to affect IL-17 signaling.

These results suggest that the Domainex inhibitors may have utility in a wide range of clinically-important diseases that have great unmet medical needs.

Recent clinical studies reported in The New England Journal of Medicine by Lilly and Amgen have shown that neutralizing anti-IL-17 monoclonal antibodies can have a major impact on psoriasis (Leonardi et al. 2012 and Papp et al. 2012 respectively).

The demonstration by Domainex that small-molecule drugs targeting IKKepsilon can inhibit IL-17 signaling indicates that these compounds have great clinical potential in this disease and other important settings.

Domainex has developed three series of drug-like compounds, each series having inhibitors with high potency and selectivity against other kinases.

The lead compounds have good metabolic properties and the Company is now driving these compounds forwards towards a clinical candidate.

Domainex's Research Director, Trevor Perrior, said: "Domainex, in collaboration with The Institute of Cancer Research, has previously shown that its inhibitors of TBK1/IKKepsilon have activity against a variety of cancer cell-lines. Domainex has also demonstrated that its inhibitors are very potent blockers of interferon-beta production in immune cells, showing the compounds may have utility in diseases such as lupus. The latest finding that our TBK1/IKKepsilon inhibitors can also inhibit IL-17 signaling suggests that the compounds are also of potential use for treatment of other major diseases such as psoriasis and COPD. Domainex has recently obtained funding from the government-backed Biomedical Catalyst programme to explore the use of its inhibitors of IKKepsilon in COPD."

Eddy Littler, CEO of Domainex, said: "The latest results showing the activity of Domainex's TBK1/IKKepsilon inhibitors against IL-17 signaling reinforces the fact that this project is of very high interest to pharma. Indeed Domainex is already in discussion with a number of potential partners with a view to them helping us to progress the programme to the clinic, and fully exploit its enormous potential. We are also grateful for the Biomedical Catalyst award that will enable us to extend our work to COPD, and help us fully exploit our intellectual property on inhibitors of TBK1 and IKKepsilon".

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Auspherix, Domainex Expand Collaboration
The companies have announced an expansion of their collaboration to develop new drugs to tackle the growing threat of resistance to antibiotics.
Wednesday, September 16, 2015
ZoBio, Domainex Partner to support FORMA Therapeutics’ Drug Discovery Programs
ZoBio and Domainex Ltd. announce a collaboration with FORMA Therapeutics to provide NMR-based structural biology services for a substantial panel of FORMA drug targets.
Monday, December 08, 2014
Auspherix and Domainex Announce Collaboration
Collaboration to develop new drugs to treat antibiotic-resistant bacterial infections.
Wednesday, October 15, 2014
Domainex Programme Shows Great Promise for the Treatment of Inflammatory Diseases
Company’s IKKe/TBK1 programme to offer a disease-modifying treatment for COPD patients.
Thursday, April 17, 2014
University of Warwick Wins Domainex’s First Discovery STAR Award
Domainex Ltd. has announced that the recipient of its first Discovery STAR Award; Professor Vilmos Fulop of the University of Warwick.
Monday, September 02, 2013
Domainex Researchers Identify Small-Molecule Inhibitors of TBK1/IKKepsilon Affecting IL-17 Signaling
Inhibitors may have utility in autoimmune disease treatment.
Monday, November 05, 2012
Domainex Awarded Technology Strategy Board Funding
£250,000 grant to support the development of a new drug for the treatment of cancers.
Friday, November 04, 2011
Domainex Wins Genesis Award for its Work in Supporting Translational Research
Domainex Ltd, the leading UK-based drug discovery CRO, has won the 2010 Genesis Life Science Innovation and Enterprise Programme Of The Year Award.
Wednesday, December 15, 2010
Domainex Collaborates with Sigma-Aldrich to Advance the Study of Epigenetic Proteins
Under the collaboration, Domainex uses CDH technology, which enables researchers to clone and express challenging proteins, to produce soluble domains of a number of proteins that have key roles in epigenetics.
Tuesday, November 16, 2010
Domainex Lead Optimization Services Facilitate a new Cancer Drug Discovery Programme
The Company is now set to provide lead optimization services in collaboration with The Institute of Cancer Research.
Thursday, April 08, 2010
Domainex Collaborates with St George’s University and The University of Manchester for Asthma Treatment
The £1.5 million collaboration focuses on a new drug discovery programme to provide a better treatment for asthma.
Friday, July 10, 2009
Domainex and Ark Therapeutics Extend Drug Discovery Agreement
Domainex continues providing Ark with hit-finding and lead optimization services for drug discovery against exciting therapeutic targets.
Thursday, July 09, 2009
Domainex Ltd Wins Biotechnology Innovation Award
The award was presented by UK Trade & Investment for developing new technologies for streamlining and accelerating the drug discovery process.
Wednesday, August 22, 2007
Scientific News
Genetic Defences of Bacteria Don’t Aid Antibiotic Resistance
Genetic responses to the stresses caused by antibiotics don’t help bacteria to evolve a resistance to the medications, according to a new study by Oxford University researchers.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Snapshot Turns T Cell Immunology on its Head
New research may have implications for 1 diabetes sufferers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
Horse Illness Shares Signs of Human Disease
Horses with a rare nerve condition have similar signs of disease as people with conditions such as Alzheimer’s, a study has found.
How a Molecular Motor Untangles Protein
Diseases such as Alzheimer’s, Parkinson’s and prion diseases, all involve “tangled” proteins.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos